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BACKGROUND. Tumor-associated differentially expressed gene–15 (TADG-15/
matriptase/MT-SP1) is a novel transmembrane serine protease involved in numer-
ous biologic processes, including activation of growth and angiogenic factors and
degradation of extracellular matrix components. To assess the value of TADG-15 as
a possible marker for tumor detection and/or as a target for therapeutic interven-
tion, the authors investigated the frequency of expression of TADG-15 in human
cervical tumors.
METHODS. TADG-15 expression was evaluated in 19 cervical carcinoma cell lines
(i.e., 11 primary tumor cell lines and 8 established cell lines) and in 8 normal
cervical keratinocyte control cultures using reverse transcriptase-polymerase chain
reaction (RT-PCR). In addition, to validate gene expression data at the protein
level, TADG-15 expression was evaluated by immunohistochemistry on parafﬁn
embedded tissue from which all 11 primary tumor cell lines were established.
RESULTS. TADG-15 was expressed at high levels in 8 of 11 (73%) primary cervical
carcinoma cell lines and in 6 of 8 (75%) established cervical carcinoma cell lines by
RT-PCR. Expression of TADG-15 was found in 6 of 6 (100%) primary squamous cell
cervical carcinomas, whereas 2 of 5 (40%) primary adenocarcinomas expressed
TADG-15. In contrast, none of the normal cervical keratinocyte control cultures (n
 4) or ﬂash-frozen normal cervical biopsy specimens (n  4) expressed TADG-15.
Immunohistochemistry staining of parafﬁn embedded cervical carcinoma speci-
mens conﬁrmed TADG-15 expression in tumor cells and its absence on normal
cervical epithelial cells.
CONCLUSIONS. Cervical carcinoma cells expressed high levels of TADG-15, suggest-
ing that this protease may play an important role in invasion and metastasis.
Because TADG-15 appears only in abundance in squamous tumor tissue and
contains a proteolytic cleavage site, suggesting that the TADG-15 protease domain
is released, it may prove to be a useful diagnostic tool for the early detection of
recurrent/persistent cervical carcinoma after standard treatment or as a novel
molecular target for therapy in patients with cervical carcinoma. Cancer 2003;98:
1898–904. © 2003 American Cancer Society.
KEYWORDS: cervical carcinoma, tumor-associated differentially expressed gene–
15, matriptase, serine protease.
H igh levels of proteolytic activity have been implicated in neoplas-tic progression. Degradation of the extracellular matrix (ECM),
including the basement membrane and interstitial stroma, is required
for metastatic tumor cells to migrate through anatomic barriers and
to invade distant tissues.1–3 Among the wide array of extracellular
matrix-degrading proteases discovered in the last few years, serine
proteases constitute a novel family of enzymes involved in numerous
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biologic processes, including activation of comple-
ment, blood coagulation, activation of growth and
angiogenic factors, and degradation of ECM compo-
nents.4,5 It is known that serine proteases contain
conserved histidine, aspartate, and serine residues
that are necessary for enzymatic activity and are either
secreted enzymes or transmembrane enzymes await-
ing cell surface release.4 In addition, it has been re-
ported that several membrane-spanning serine pro-
teases have cytoplasmic N-terminal domains,
suggesting possible functions in intracellular signal
transduction.4 Because a high level of serine protease
expression in several human solid tumors compared
with normal control cells has been demonstrated,
these enzymes recently have been proposed as poten-
tial diagnostic, prognostic, and/or therapeutic targets
for several human tumors.5–11 Consistent with this
view, two members of the serine protease family, pros-
tate-speciﬁc antigen (PSA) and human kallikrein 2,
already serve important clinical functions as prostate
carcinoma biomarkers,5 whereas other serine pro-
teases (i.e., kallikrein 6, kallikrein 10, kallikrein 11, and
kallikrein 14) are in the process of being validated as
novel biomarkers for ovarian carcinoma.8–12
Tumor-associated differentially expressed
gene–15 (TADG-15; matriptase/MT-SP1) is a trypsin-
like serine protease with a cytoplasmic domain; a
transmembrane domain with a cleavage site for re-
lease of extracellular domains; four low-density li-
poprotein receptor-like, ligand-binding domains; and
a serine protease domain.13 The ligand-binding and
serine protease domains all are extracellular and are
released after proteolytic cleavage. Initially isolated by
Shi et al.14 as a novel protease expressed by human
breast carcinoma cells, TADG-15 now has been
cloned, and it has been shown that TADG-15 func-
tions as an epithelial membrane activator for other
proteases and latent growth factors.15–18 Consistent
with this view, it has been shown that TADG-15 acti-
vates the latent form of hepatocyte growth factor
(HGF) to produce the active growth and motility factor
that can bind to and activate the c-Met receptor.16
TADG-15 has also been characterized as an in vitro
activator of the calcium-regulating, protease-activated
receptor-2 (PAR-2) as well as of the serine protease
urokinase-type plasminogen activator (uPA), linking
the latter to the activation of other protease systems
important for tumor cell invasion and metastases.16,17
Our group recently developed a screening strategy
using redundant primers to the conserved catalytic
triad domain of the serine protease family. Using this
approach to display serine protease transcripts that
are found in abundance in gynecologic tumor tissues
but that have little or no expression in normal tissues,
we recently reported the identiﬁcation and cloning of
several transmembrane serine proteases, including
TADG-15, in ovarian carcinoma.18–22 In the current
study, with the goal of assessing the value of serine
proteases as possible markers for tumor detection
and/or targets for therapeutic intervention, we have
evaluated the extent and frequency of expression of
the TADG-15 gene in several primary and established
squamous and adenocarcinoma cervical carcinoma
cell lines. To our knowledge, we report for the ﬁrst
time the expression of TADG-15 in the majority of
cervical tumors evaluated. These ﬁndings may have
important implications for the use of TADG-15 pro-
tease as a diagnostic tool or as a molecular target for
therapy in patients with cervical carcinoma.
MATERIALS AND METHODS
Primary and Established Cervical Carcinoma Cell Lines
Nineteen cervical carcinoma cell lines (11 primary
tumor cell lines and 8 established cell lines) were
evaluated for TADG-15 expression by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) analy-
sis. Established, commercially available cervical carci-
noma cell lines (i.e., CaSki, SiHa, MS-751, HT-3, C33a,
Me180, HeLa, and C4-I) were purchased from the
American Type Culture Collection. Tumors derived
from primary specimens were staged according to the
International Federation of Gynecology and Obstetrics
operative staging system. Fresh tumor biopsy speci-
mens from patients who were diagnosed with frankly
invasive, Stage IB–IIA cervical carcinoma were ob-
tained at the time of surgery through the Gynecologic
Oncology Division and the Pathology Department at
the University of Arkansas for Medical Sciences
(UAMS) under approval of the Institutional Review
Board. Patient characteristics are described in Table 1.
TABLE 1
Patient Characteristics
Patient
Age
(yrs) Race
Disease
stage HPV type Treatment
CVX-1 40 White IB 16 Surgery
CVX-2 26 White IB 16 Surgery
CVX-3 47 African American IB 16 Radiotherapy
CVX-4 38 African American IB 16 Surgery
CVX-5 40 White IIA 16 Surgery
CVX-6 42 White IB 18 Surgery
ADX-1 33 White IB 18 Surgery
ADX-2 33 African American IB 18 Surgery
ADX-3 27 White IB 18 Surgery
ADX-4 50 African American IB 18 Surgery
ADX-5 46 White IB 18 Surgery
HPV: human papillomavirus; CVX: squamous cell cervical carcinoma; ADX: adenocarcinoma.
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All but one patient underwent radical abdominal hys-
terectomy and lymph node dissection for invasive cer-
vical carcinoma. Eight normal keratinocyte control
samples (i.e., four primary keratinocyte cultures and
four ﬂash-frozen biopsy specimens) were obtained
from cervical biopsies of hysterectomy specimens
from women who were diagnosed with benign disease
and had a previous report of a normal cytologic eval-
uation. Cervical carcinoma cell lines and normal ker-
atinocyte cell lines were established by following pre-
viously reported, standard tissue culture techniques.23
We studied 11 primary cervical carcinoma cell lines
and 4 primary keratinocyte cell lines: Some had been
cultured for 3–4 weeks, and others had been cultured
for a much longer time. The purity of fresh tumor
cultures was tested by morphology, immunohisto-
chemistry staining, and/or ﬂow cytometry with anti-
bodies against cytokeratins. Only cell lines that con-
tained  99% tumor cells were evaluated. Because
tissue digestion and prolonged in vitro cell culture
potentially may alter antigen expression, four adjunc-
tive normal cervical keratinocyte biopsy specimens
also were evaluated as negative controls for TADG-15
expression before enzymatic digestion and/or in vitro
culture (i.e., they were snap frozen in liquid nitrogen
immediately after collection).
RNA Isolation and cDNA Synthesis
RNA isolation from different cell lines was performed
using TRIzol Reagent (Invitrogen, San Diego, CA) ac-
cording to the manufacturer’s instructions. To verify
integrity, 4 g of RNA from each sample were run in
1% agarose gels using 18S28S Ribosomal RNA (Sig-
ma, St. Louis, MO) as a positive control. First-strand
cDNA was synthesized using 5 g of total RNA, 1
 RT-PCR buffer, 5 mM MgCl2, 1 mM dNTPs, 2.5 M
random hexamers, 1 unit (U)/L Rnase inhibitor, and
2.5 U/L MulLV Reverse transcriptase (GeneAmp RNA
PCR kit; Applied Biosystems, Foster City, CA) in a total
volume of 20 L. RNA extracted from the CaOV3 se-
rous papillary ovarian carcinoma cell line, previously
reported to express TADG-15,18 was used as a positive
control.
PCR Analysis
The PCR reaction mixture consisted of cDNA, 0.4 M
of sense and antisense primers, 2.5 mM MgCl2, 0.2
mM dNTPs, 0.025 U/L Taq polymerase (GeneAmp
RNA PCR kit; Applied Biosystems) with reaction buffer
in a total volume of 50 L. The target sequences were
ampliﬁed in parallel with -tubulin gene.
Thirty cycles of PCR for speciﬁc targets were per-
formed in a GeneAmp PCR System 2700 (Applied Bio-
systems). Each PCR cycle included 30 seconds of de-
naturation at 95 °C, 30 seconds of annealing at 67 °C,
and 30 seconds of extension at 72 °C. The sequences of
the TADG-15-speciﬁc primers that produced the 150–
base pair (bp) product were as follows: 5-ATGACA-
GAGGATTCAGGTAC-3 forward and 5-GAAGGT-
GAAGTCATTGAAGA-3 reverse. The sequences of
-tubulin primers that produced the 454-bp product
were as follows: 5-CGCATCAACGTGTACTACAA-3
(forward) and 5-TACGAGCTGGTGGACTGAGA-3 (re-
verse).
Antibody Production and Immunohistochemistry
Polyclonal antibodies were generated by immuniza-
tion of white New Zealand rabbits with poly-lysine–
linked, multiple-antigen peptides derived from the
amino acid sequence of TADG-15 (LFRDWIKENTGV),
as reported previously.18 Formalin ﬁxed, parafﬁn em-
bedded tissue blocks from 8 normal uterine cervices
(i.e., controls) and from 11 invasive cervical carcino-
mas of the uterus (6 squamous carcinomas and 5
adenocarcinomas), from which primary cell lines were
established, were retrieved from the surgical pathol-
ogy ﬁles of UAMS and evaluated for TADG-15 expres-
sion. Study blocks were selected after histopathologic
review. The most representative hematoxylin and eo-
sin-stained block sections were used for each speci-
men. Immunohistochemical staining was performed
using a Vectastain Elite avidin-biotin complex (ABC)
Kit (Vector Laboratories, Burlingame, CA). Brieﬂy, for-
malin ﬁxed and parafﬁn embedded specimens were
deparafﬁnized and processed routinely using micro-
wave heat treatment in 0.01 M sodium citrate buffer,
pH 6.0. The specimens were incubated in methanol
with 0.3% H2O2 for 30 minutes at room temperature
and then incubated with normal goat serum for 30
minutes. The samples were incubated with anti-
TADG-15 peptide-derived polyclonal antibody for 1
hour at room temperature in a moisture chamber.
This was followed by incubation with biotinylated an-
tirabbit immunoglobulin G for 30 minutes, then incu-
bation with ABC reagent for 30 minutes. The ﬁnal
products were visualized using the AEC substrate sys-
tem (Dako, Carpenteria, CA), and sections were coun-
terstained with hematoxylin before mounting. Nega-
tive controls were performed by using normal serum
instead of the primary antibody.
Statistical Analysis
Data were analyzed using the two-tailed t test and the
Student t test for paired data. In all tests, the difference
was considered signiﬁcant when P values were  0.05.
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RESULTS
TADG-15 Expression in Primary and Established Cervical
Carcinoma Cell Lines
To characterize the frequency of expression of the
TADG-15 gene in cervical tumors, we used RT-PCR
with cDNA derived from primary and established
squamous and adenocarcinoma cervical carcinoma
cell lines as a template. Cultures of normal cervical
keratinocytes were used as controls. PCR primers that
amplify a TADG-15-speciﬁc, 150 bp product were syn-
thesized and used in reactions. Primers that produce a
speciﬁc, 454 bp PCR product for -tubulin also were
used as internal controls. Of the 19 cervical carcino-
mas studied, 15 carcinomas (79%) expressed TADG-15
by RT-PCR. Figure 1 shows an ethidium bromide–
stained agarose gel with the separated RT-PCR prod-
ucts for normal cervical keratinocytes and primary
cervical carcinoma cell lines, and Figure 2 shows the
RT-PCR results for the established cervical carcinoma
cell lines. Both are representative of the typical results
observed. Flash-frozen samples or cultures of normal
cervical keratinocytes did not express TADG-15 (Figs.
1, 2). In contrast, TADG-15 was expressed in 8 of 11
(73%) primary cervical carcinoma cell lines (P  0.01)
and in 7 of 8 (87%) established cervical carcinoma cell
lines (P  0.01). For individual histologic subtypes of
primary tumors, TADG-15 expression by primary
squamous cell cervical carcinomas was found in 6 of 6
cell lines (100%), whereas 2 of 5 adenocarcinoma cell
lines (40%) expressed TADG-15.
Immunohistochemical Staining
To determine whether TADG-15 expression detected
by RT-PCR in primary cervical carcinoma cell lines
was the result of the selection of a subpopulation of
tumor cells present in the original tumor or whether in
vitro expansion conditions may have modiﬁed gene
expression, we performed immunohistochemical
analysis of TADG-15 protein expression on formalin-
ﬁxed, parafﬁn-embedded tumor tissues from all pri-
mary tumors from which primary cell lines were de-
rived. Table 2 shows that immunohistochemical
staining supported the data obtained by RT-PCR. Us-
ing a TADG-15 peptide-directed antibody, we ob-
served no signiﬁcant staining with normal cervical
keratinocytes samples (Fig. 3A). In contrast, intense
staining was associated with cervical tumor cells of
both adenocarcinoma and squamous histologic sub-
types (Fig. 3C,D). Both adenocarcinomas and squa-
mous cell carcinomas (Fig. 3C,D, respectively), similar
to ovarian carcinoma cells (i.e., positive controls) (Fig.
3B), showed diffuse cytoplasmic staining for TADG-15.
FIGURE 1. Tumor-associated differentially expressed gene–15 (TADG-15) expression was determined by reverse transcriptase-polymerase chain reaction analysis
of primary squamous cell carcinoma (CVX1–CVX6), primary adenocarcinoma (ADX1–ADX5), and normal cervical keratinocyte primary cell lines. The reaction products
were electrophoresed through a 2% agarose gel and stained with ethidium bromide. The 454-base pair (bp) band represents the -tubulin product, and the 150-bp
band represents the TADG-15 product. TADG-15 mRNA expression was not detected in any of the 4 normal cervical keratinocyte cell lines tested. In contrast, 6
of 6 (100%) squamous cell carcinoma cell lines and 2 of 5 (40%) cervical adenocarcinoma cell lines consistently expressed TADG-15.
FIGURE 2. Tumor-associated differentially expressed gene–15 (TADG-15) expression was determined by reverse transcriptase-polymerase chain reaction analysis
on established cervical carcinoma cell lines and normal keratinocyte ﬂash-frozen biopsy specimens. The reaction products were electrophoresed through a 2%
agarose gel and stained with ethidium bromide. The 454–base pair (bp) band represents the -tubulin product, and the 150 bp band represents the TADG-15
product. TADG-15 mRNA expression was not detected in any of the 4 normal cervical keratinocyte samples tested. In contrast, 6 of 8 (75%) established cell lines
expressed TADG-15.
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DISCUSSION
The activity of proteolytic enzymes is required at mul-
tiple stages during the growth, invasion, and progres-
sion of human tumors. Consistent with this view, sev-
eral reports have demonstrated a positive correlation
between the progression of malignant disease and the
expression of extracellular proteases, such as matrix
metalloproteinases (MMPs) and serine proteases
(uPA), in a variety of human tumors.1–5 Furthermore,
it has been shown that inhibitors of these proteolytic
enzymes interfere with the spread of malignancy in
animal models.24 These ﬁndings have prompted ef-
forts to develop novel antitumor therapies directed
against the proteolytic cascade initiated by MMPs and
serine proteases and the various signaling pathways
mediated by these enzymes.
Recently, the organization of the serine protease
gene family (i.e., the kallikrein family) has been eluci-
dated fully.5 This family contains 15 genes that encode
secreted serine proteases, which share signiﬁcant ho-
mologies at both the DNA level and the amino-acid
level. It is noteworthy that several members of this
family reportedly are expressed highly differentially in
human malignancies, including breast, ovarian, and
prostate carcinomas, compared with normal tissue
control cells.5–15 Among these proteases, TADG-15 has
received much attention because of its ability to cleave
and activate uPA, the protease-activated receptor-2
(PAR-2), and the HGF activator (HGF/SF).16,17 Many
studies have implicated uPA, PAR-2, and HGF in the
metastatic process, in angiogenesis, and in the growth
and motility of various human tumors.16,17,25–27 Thus,
TADG-15 may play a crucial role in the growth and/or
invasion of human malignancies through its activation
of pro-uPA, pro-PAR-2, and pro-HGF. In a ﬁnding
consistent with this view, we recently identiﬁed over-
expression of TADG-15 and other secreted proteases
in a high percentage of ovarian carcinomas.18–22 Be-
cause of the paucity of information on serine protease
expression in cervical carcinomas, in this work, we
have analyzed the expression of the serine protease
TADG-15 in several short-term primary cultures as
well as established cervical carcinoma cell lines. In
this pilot work, we chose this approach to evaluate
differential TADG-15 gene expression in highly en-
riched populations of cervical tumor-derived epithe-
lial cells. We report for the ﬁrst time that TADG-15 was
expressed in 15 of 19 (79%) cervical carcinomas stud-
ied, whereas it was undetectable in normal cervical
keratinocytes. Therefore, these data support the view
that TADG-15 is a serine protease that is expressed
highly differentially in cervical tumors compared with
normal control cells (i.e., cervical keratinocytes). Fur-
thermore, to validate gene expression data at the pro-
tein expression level, TADG-15 expression was evalu-
ated by immunohistochemistry on parafﬁn embedded
tissue from which all 11 primary tumor cell lines were
established. All primary, uncultured tumor specimens
from which TADG-15 expression was detected by RT-
PCR expressed detectable TADG-15 by immunohisto-
chemistry. These data conﬁrm that TADG-15 is ex-
pressed in TADG-15 RNA positive cervical carcinoma
cells. It is noteworthy that 100% of the primary squa-
mous cervical carcinomas and 40% of the primary
adenocarcinomas tested positive for TADG-15. Thus,
these data suggest that the majority of squamous cer-
vical tumors and a signiﬁcant number of adenocarci-
nomas may overexpress TADG-15. The value of
TADG-15 as a diagnostic or therapeutic target may
depend on differential expression between different
stages of cervical carcinoma and dysplasia. However,
to date, no data are available on TADG-15 expression
by cervical intraepithelial lesions.
Although surgery and radiation therapy represent
effective treatment modalities for patients with cervi-
cal carcinoma, up to 35% of patients overall will de-
velop recurrent, metastatic disease, for which treat-
ment results remain poor.28 However, in patients who
have recurrent disease that is limited to the central
pelvis, and in patients who have not previously re-
ceived radiotherapy as primary or adjunctive treat-
ment, cure potentially is achievable with ultraradical
TABLE 2
Tumor-Associated Differentially Expressed Gene–15 Expression in
Squamous Cell Carcinoma and Adenocarcinoma of the Cervix and
Normal Keratinocytes as Determined by Immunohistochemistry
Tissue type TADG-15 expression
CVX-1 Positive
CVX-2 Positive
CVX-3 Positive
CVX-4 Positive
CVX-5 Positive
CVX-6 Positive
ADX-1 Positive
ADX-2 Negative
ADX-3 Negative
ADX-4 Positive
ADX-5 Negative
KRT-1 Negative
KRT-2 Negative
KRT-3 Negative
KRT-4 Negative
KRT-5 Negative
KRT-6 Negative
KRT-7 Negative
KRT-8 Negative
TADG-15: tumor-associated differentially expressed gene–15; CVX: cervical squamous cell carcinoma;
ADX: adenocarcinoma; KRT: normal keratinocytes.
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(i.e., exenterative) surgery or radiation therapy, re-
spectively. Because of the tendency of cervical carci-
noma to invade adjacent deep pelvic tissues directly
and to spread by lymphatics, accurate assessment of
disease status remains problematic. This is especially
true in previously irradiated patients, in whom the
distinction between radiation ﬁbrosis and disease re-
currence may be extremely difﬁcult. A serum tumor
marker that accurately reﬂects the active tumor status
of the majority of patients with cervical carcinoma
would be particularly useful in this setting. Because
TADG-15 appears in abundance in squamous cell car-
cinoma, and because TADG-15 can be released, as
suggested by immunohistochemical data,13–15,18 we
speculate that this protease may prove to be a useful
tool for the early detection of recurrent and/or persis-
tent cervical carcinoma. Consistent with this view, PSA
and kallikrein 2 already have been validated as tumor
markers for the early diagnosis of prostate carcinoma
due to their abnormal prevalence in the peripheral
blood of patients;5 whereas other secreted members of
the serine proteases family including kallikrein 6, kal-
likrein 10, kallikrein 11, and kallikrein 14, are in the
process of being validated as novel biomarkers in
other human solid tumors.8–12 To validate this hy-
pothesis, an enzyme-linked immunosorbent assay de-
tection kit for quantiﬁcation of TADG-15 in the circu-
lation of patients with ovarian and cervical carcinoma
is under development in our laboratory. However, fu-
ture studies will be necessary to evaluate the potential
of TADG-15 as a novel tumor marker in cervical car-
cinoma.
The recognition of tumor antigen-loaded den-
dritic cells (DCs) as one of the most promising ap-
proaches to induce a tumor-speciﬁc immune re-
sponse in vivo recently has generated widespread
interest in the use of these ‘natural adjuvants’ for the
treatment of several human malignancies that are re-
fractory to standard treatment modalities.29 The iden-
tiﬁcation and cloning of a group of preferentially ex-
pressed serine proteases, including TADG-15, as novel
tumor-associated antigens, therefore, may offer the
opportunity to use these targets to assess the potential
of therapeutic DC vaccination for the treatment of
patients with malignant disease that is refractory to
standard treatment modalities.30 In a ﬁnding concor-
dant with this view, our laboratory recently has iden-
tiﬁed cytotoxic T lymphocyte (CTL) epitopes against
some serine proteases, including hepsin and kallikrein
7 (SCCE), genes that are expressed highly differentially
in ovarian carcinomas and pancreatic carcinoma.30
These data, combined with the recently reported im-
munodominant role played by the serine protease PSA
in the prostate carcinoma-speciﬁc immune response
induced by DCs transfected with ampliﬁed tumor
RNA31 or loaded with killed prostate carcinoma cells,32
further suggest that peptide epitopes derived from
TADG-15 may become selective targets for DC-driven,
CD8 positive CTLs against cervical carcinoma.
In conclusion, we have shown that 100% of pri-
mary squamous tumors of the uterine cervix and 40%
of cervical adenocarcinoma cell lines, but not normal
cervical epithelial cells, overexpress the TADG-15
gene. We have also demonstrated that these tumors
expressed this transmembrane serine protease. On the
basis of these ﬁndings, we suggest that TADG-15 has
FIGURE 3. Immunohistochemical anal-
ysis of tumor-associated differentially ex-
pressed gene–15 (TADG-15) expression in
cervical tumors. Representative immuno-
reactivity for TADG-15 in (A) normal epi-
thelial cells, (B) ovarian serous papillary
carcinomas (positive control), (C) adeno-
carcinoma ADX-1 cells, and (D) cervical
squamous cell carcinoma CVX-2 cells.
Although no staining was observed in nor-
mal cervical keratinocytes, in both squa-
mous cell carcinoma and adenocarcinomas,
TADG-15 exhibited diffuse staining through-
out all tumor cells. Original magniﬁcation
400.
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the potential to become a useful diagnostic tool for
monitoring response to therapy and for detecting
early recurrences after treatment, and TADG-15 also
may serve as a novel target antigen for the therapy of
patients with cervical tumors that are refractory to
standard treatment modalities. The future design and
implementation of clinical trials ultimately will deter-
mine the validity of this approach.
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